
Chapter 69 THE ALCOHOLS: ETHANOL, ETHYLENE GLYCOL, METHANOL, AND ISOPROPYL ALCOHOL482
10. How should AKA be managed?
Treatment consists of rehydration with dextrose-containing crystalloid, antiemetics if needed,
benzodiazepines for withdrawal, and multivitamins, potassium, and phosphate as indicated.
Bicarbonate is rarely required, and insulin therapy is proscribed. Metabolic abnormalities
usually resolve with 12 to 16 hours of therapy.
11. What is the relationship between alcohol and metabolic acidosis?
n
Ethanol: Acute ethanol ingestion results in a mild increase in the lactate-to-pyruvate ratio.
Clinically significant metabolic acidosis does not ensue.
n
AKA: This ethanol abstinence syndrome produces marked elevations in acetoacetate and
b-hydroxybutyrate with resultant and occasionally profound increased anion gap metabolic
acidosis. During the correction phase, a non-anion gap, hyperchloremic picture often
develops (because some of the bicarbonate-bound ketoacids are excreted in the urine) on
the road to normalization.
n
Ethylene glycol and methanol: Toxic metabolites of these compounds produce increased
anion-gap metabolic acidosis. In the suspected alcoholic patient who presents with
significant metabolic acidosis, a quick method of distinguishing the presence of ethylene
glycol or methanol from AKA is the osmolal gap. If this exceeds 25 mOsm/Kg, it is 88%
specific for the presence of ethylene glycol or methanol.
n
Isopropyl alcohol: A significant portion of isopropyl alcohol is metabolized to acetone.
This is a ketone but not a ketoacid, causing ketosis and ketonuria but not acidosis.
12. How is coagulation affected in a chronic alcoholic?
Bone marrow depression from ethanol, folate deficiency, and hypersplenism secondary to
portal hypertension all cause thrombocytopenia. Platelet counts less than 30,000/mL,
resulting from alcohol usage alone, are unlikely. Qualitative platelet defects also occur.
Hepatocyte loss from chronic alcohol abuse depletes all coagulation factors except VIII,
particularly II, VII, IX, and X. Alcoholics often have inadequate vitamin K, a requisite cofactor
for the production of factors II, VII, IX, and X because of hepatobiliary dysfunction and poor
diet. When faced with gastrointestinal hemorrhage in a chronic alcoholic, an intravenous
vitamin K supplementation trial is warranted. The far more likely culprit is hepatocellular
destruction, however, for which vitamin K would not be helpful. Vitamin K does not begin to
restore factor levels for 2 to 6 hours, so for emergent scenarios, fresh frozen plasma provides
immediate factor supplementation.
13. How should the combative alcoholic patient be managed?
When the patient or staff is in jeopardy, the first step is physical restraint of the patient.
A sufficient number of competent personnel and restraint devices are necessary. Closed
head injury, hypoxia, or a full bladder may be the source of distress and should be excluded,
managed, or relieved.
For chemical sedation, haloperidol (5–10 mg intravenous push) has rapid onset of
sedation (5 minutes), but repeat doses may be required. This agent is not detrimental to
airway patency, ventilation, or hemodynamics. There is a 5% to 10% incidence of
extrapyramidal reactions, usually within 12 to 24 hours. Droperidol (2.5–5 mg
intramuscularly) is another effective butyrophenone, but it received a black-box warning
in 2004 due to reports of QT prolongation and torsades de pointes. In any case, haloperidol
and droperidol have been shown to be relatively comparable in efficacy and side effects.
14. When is an intoxicated patient safe to discharge from the ED?
From a management perspective, there are two fundamental concerns:
n
Acute intoxication obfuscates the verification of certain diagnoses and the exclusion of
others.
n
A physician who discharges an acutely intoxicated (i.e., incompetent) patient may be
held accountable for the actions of that patient subsequent and proximate to discharge
from the ED.